Business Wire

Norway Starts Free-Flow Tolling In One Of World´s Deepest Undersea Tunnels - Kapsch TrafficCom reports

8.3.2021 11:10:00 EET | Business Wire | Press release

Share

The Norwegian Public Roads Administration (Statens Vegvesen) assigned Kapsch TrafficCom (Kapsch) in October 2020 to deliver a new Multi-Lane Free-Flow (MLFF) tolling system at Ryfast, Norway. Only 13 weeks after the contract signature, the system with 6 tolling points went successfully into operation on February 1, 2021.

The Ryfast sub-sea tunnel system runs from the city of Stavanger to the municipality of Strand. It is one of the longest and deepest undersea road tunnels in the world, with the Ryfylke tunnel of 14.3 kilometres length and 292 meters deep. After implementing the high performance system in record time of only 13 weeks, the Kapsch MLFF G3 tolling system is now in operation since the beginning of February.

“While we have installed our systems at tunnels, bridges, cities and roadways all around the world, we are proud to be part of the Ryfast project. We are very happy that we have managed to implement a reliable and high-performing system in such a short time", says Mikael Hejel, responsible Area Sales Manager for the Nordic countries.

The tolling system detects and identifies all passing vehicles with video technology, which classifies the vehicles and captures their front- and rear license plates. Through microwaves, the tolling system also detects and reads AutoPass toll tags, which are linked to the vehicle’s license plate number. The information captured by the tolling system is transmitted to a back-office for further processing and invocing of the vehicle owners.

“Due to that a previous tolling system could not be set into operation, we had to retender a new tolling system and allocate a tight time schedule. In addition, given the current Covid situation and closed borders, it was a challenging task both for Statens vegvesen and Kapsch to comply with the schedule. Therefore we are very pleased with the open dialogue and the transparency we have had with Kapsch TrafficCom, something which enabled the extremely short implementation time of the new tolling system”, says Kristian Rognskog, Chief Engineer of AutoPASS/Bompeng systems at Statens vegvesen.

For additional information: www.kapsch.net/ktc?lang=en-us

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Area Sales Manager Nordic Countries
Mikael Hejel

M +46 768 79 44 45
Email: mikael.hejel@kapsch.net

Press Contact
Mohamed Thaler-Youssef

Phone +43 50 811 1705
Email: mohamed.thaler-youssef@kapsch.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release

Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release

Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye